Matica Bio Appoints Life Sciences Veteran Paul Kim as Chief Executive Officer
View the full release here: https://www.businesswire.com/news/home/20240205648112/en/
- View the full release here: https://www.businesswire.com/news/home/20240205648112/en/
Paul Kim, Matica Bio's new CEO (Photo: Business Wire)
As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands its capacity and capabilities in the U.S. and Korea. - Yun Jeong Song, outgoing president and CEO, will take on a new role as president of Matica Holdings.
- Kim brings to Matica Bio nearly three decades of experience across the CDMO, CRO and R&D biopharma sectors as CEO, managing director, chief business officer, managing partner and executive board member at WCCT Global, Genopis, Cobra Biologics, Cognate BioServices, and Novartis Venture Fund.
- Kim is also the founder of Forward Equity Partners (formerly Medivate Partners), a private equity firm focused on cross-border healthcare and life sciences investments – the first ever in Korea.